Kamada’s share price has plunged 40% in the past three months, following failure in a drug trial.
Brosh Capital, led by portfolio manager and managing partner Amir Efrati, together with partners Asaf Frumerman and Shahar Keinan, has acquired a 6.2% holding in pharma company Kamada Ltd. (Nasdaq: KMDA); TASE: KMDA) for NIS 40 million, sources inform “Globes.” Kamada’s share price has plunged 40% in the past three months. Brosh, which is also an active investor in Alcobra Pharmaceuticals Ltd. (Nasdaq: ADHD), Perion Network Ltd. (Nasdaq:PERI: TASE:PERI), and Matomy Media Group (LSE:MTMY; TASE: MTMY), is known for investing in companies when it believes that it can improve their management. Kamada’s share price responded to the news with a 5% jump, raising the company’s market cap to NIS 663 million.
continue reading